Vascular Medicine Institute, USA; Department of Pharmacology & Chemical Biology, USA.
Vascular Medicine Institute, USA.
Redox Biol. 2019 Apr;22:101143. doi: 10.1016/j.redox.2019.101143. Epub 2019 Feb 15.
First described as essential to the phagocytic activity of leukocytes, Nox2-derived ROS have emerged as mediators of a range of cellular and tissue responses across species from salubrious to deleterious consequences. Knowledge of their role in inflammation is limited, however. We postulated that TNFα-induced endothelial reactive oxygen species (ROS) generation and pro-inflammatory signaling would be ameliorated by targeting Nox2. Herein, we in silico-modelled two first-in-class Nox2 inhibitors developed in our laboratory, explored their cellular mechanism of action and tested their efficacy in in vitro and mouse in vivo models of inflammation. Our data show that these inhibitors (CPP11G and CPP11H) disrupted canonical Nox2 organizing factor, p47, translocation to Nox2 in the plasma membrane; and abolished ROS production, markedly attenuated stress-responsive MAPK signaling and downstream AP-1 and NFκB nuclear translocation in human cells. Consequently, cell adhesion molecule expression and monocyte adherence were significantly inhibited by both inhibitors. In vivo, TNFα-induced ROS and inflammation were ameliorated by targeted Nox2 inhibition, which, in turn, improved hind-limb blood flow. These studies identify a proximal role for Nox2 in propagated inflammatory signaling and support therapeutic value of Nox2 inhibitors in inflammatory disease.
最初被描述为白细胞吞噬活性所必需的,Nox2 衍生的 ROS 已经成为从有益到有害后果的各种物种的细胞和组织反应的介质。然而,人们对其在炎症中的作用知之甚少。我们假设,通过靶向 Nox2,可以改善 TNFα 诱导的内皮细胞活性氧(ROS)生成和促炎信号。在此,我们通过计算机模拟了我们实验室开发的两种首创的 Nox2 抑制剂,探索了它们的细胞作用机制,并在体外和体内炎症模型中测试了它们的功效。我们的数据表明,这些抑制剂(CPP11G 和 CPP11H)破坏了 Nox2 组织因子,p47,向质膜中 Nox2 的易位;并消除了 ROS 的产生,显著减弱了应激反应性 MAPK 信号和下游 AP-1 和 NFκB 的核易位在人类细胞中。结果,细胞黏附分子的表达和单核细胞黏附均受到两种抑制剂的显著抑制。在体内,靶向 Nox2 抑制可改善 TNFα 诱导的 ROS 和炎症,进而改善后肢血流。这些研究确定了 Nox2 在传播性炎症信号中的近端作用,并支持 Nox2 抑制剂在炎症性疾病中的治疗价值。